NCT05324293View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 11, 2022

Primary Completion Date

September 11, 2023

Study Completion Date

September 11, 2023

Conditions
Androgenetic Alopecia
Interventions
DRUG

HMI-115

Once Every 2 weeks, subcutaneously injection

Trial Locations (1)

Unknown

Dr Rodney Sinclair Pty Ltd, trading as Sinclair Dermatology, Melbourne E.

All Listed Sponsors
lead

Hope Medicine (Nanjing) Co., Ltd

INDUSTRY